Frequency of Urinary Tract Infections in Diabetic Patients Taking SGLT-2 Inhibitors
DOI:
https://doi.org/10.70749/ijbr.v3i7.2324Keywords:
Diabetes Mellitus, Empagliflozin, Prevalence, SGLT-2 Inhibitors, Urinary Tract InfectionsAbstract
Background: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are widely prescribed for type 2 diabetes mellitus due to their glucose-lowering, cardiovascular, and renal benefits. However, concerns remain regarding an increased risk of urinary tract infections (UTIs), particularly in diabetic patients already predisposed to infections. Evidence from local populations is limited, necessitating focused evaluation. Objective: To determine the frequency of urinary tract infections in diabetic patients taking SGLT-2 inhibitors. Study Design: Descriptive cross-sectional study. Duration and Place of Study: This study was conducted from February 2025 to May 2025 in the Department of Medicine, Shaikh Zayed Federal Postgraduate Medical Institute, Lahore. Methodology: A total of 193 patients aged 20–70 years with type 2 diabetes mellitus receiving SGLT-2 inhibitors for at least three months were enrolled through non-probability consecutive sampling. Demographic characteristics, clinical history, and anthropometric measures were recorded. UTIs were identified based on clinical symptoms such as fever or dysuria within four weeks and confirmed through urine analysis and culture. Results: The mean age was 56.01±9.07 years, with females representing 54.4% of the cohort. The overall frequency of UTIs was 10.9% (n=21). Female gender (p=0.038) and SGLT-2 therapy exceeding 12 months (p=0.010) were significantly associated with higher infection rates. No significant association was found with age, BMI, or residence. Conclusion: UTIs were observed in approximately one-tenth of diabetic patients on SGLT-2 inhibitors, with higher risk in females and long-term users.
Downloads
References
1. Hossain, M. J., Al‐Mamun, M., & Islam, M. R. (2024). Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health Science Reports, 7(3).
https://doi.org/10.1002/hsr2.2004
2. Matoori, S. (2022). Diabetes and its complications. ACS Pharmacology & Translational Science, 5(8), 513-515.
https://doi.org/10.1021/acsptsci.2c00122
3. Siam, N. H., Snigdha, N. N., Tabasumma, N., & Parvin, I. (2024). Diabetes mellitus and cardiovascular disease: Exploring epidemiology, pathophysiology, and treatment strategies. Reviews in Cardiovascular Medicine, 25(12).
https://doi.org/10.31083/j.rcm2512436
4. Ahmad, F., & Joshi, S. H. (2023). Self-care practices and their role in the control of diabetes: A narrative review. Cureus.
https://doi.org/10.7759/cureus.41409
5. Chong, K., Chang, J. K., & Chuang, L. (2024). Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies. The Kaohsiung Journal of Medical Sciences, 40(3), 212-220.
https://doi.org/10.1002/kjm2.12800
6. Srinivas, N., Sarnaik, M. K., Modi, S., Pisipati, Y., Vaidya, S., Syed Gaggatur, N., Sange, A. H., & Sange, I. (2021). Sodium-glucose Cotransporter 2 (SGLT-2) inhibitors: Delving into the potential benefits of Cardiorenal protection beyond the treatment of type-2 diabetes mellitus. Cureus.
https://doi.org/10.7759/cureus.16868
7. Danpanichkul, P., Manosroi, W., Nilsirisuk, T., & Tosukhowong, T. (2024). Predictors of weight reduction effectiveness of SGLT2 inhibitors in diabetes mellitus type 2 patients. Frontiers in Endocrinology, 14.
https://doi.org/10.3389/fendo.2023.1251798
8. Andreea, M. M., Surabhi, S., Razvan-Ionut, P., Lucia, C., Camelia, N., Emil, T., & Tiberiu, N. I. (2023). Sodium-glucose Cotransporter 2 (SGLT2) inhibitors: Harms or unexpected benefits? Medicina, 59(4), 742.
https://doi.org/10.3390/medicina59040742
9. Hazique, M., Surana, A., Sinha, M., & Anand, A. (2023). Recurrent urinary tract infection associated with SGLT-2 inhibitor in type 2 diabetes mellitus patient: A case report. Clinical Case Reports, 11(1).
https://doi.org/10.1002/ccr3.6803
10. Tanrıverdi, M., Baştemir, M., Demirbakan, H., Ünalan, A., Türkmen, M., & Tanrıverdi, G. Ö. (2023). Association of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes. BMC Endocrine Disorders, 23(1).
https://doi.org/10.1186/s12902-023-01464-6
11. Wazir, Z. M., khan, I., Alam, B., Ullah, I., Ullah, A., & Ahmad, J. (2022). Frequency of urinary tract infections in type 2 diabetes mellitus patients, using sglt-2 inhibitors. Journal of Population and Therapeutics and Clinical Pharmacology.
https://doi.org/10.53555/jptcp.v31i3.6008
12. Aziz, A., Kazi, A., Asim, A., Javed, R., Zarar, F., & Saqlain, F. Frequency of UTI in Diabetic Patients taking SGLT2 Inhibitors. Age (years), 50(94), 75-2.
https://doi.org/10.70302/jpsim.v5i1.2404
13. Ashfaq, M., Shafique, S., Niazi, Z., Shah, S. Y., Memon, S., Qureshi, K., & Banaras, F. (2023). Occurence of urinary tract infections in type 2 diabetes mellitus patients taking sodium-glucose Co-transporter-2 (SGLT-2) inhibitors to regulate their blood sugar levels. International journal of health sciences, 7(S1), 1999-2005.
https://doi.org/10.53730/ijhs.v7ns1.14444
14. Dayo, A. R., Sanghro, K. A., Chandio, B. A., Tunio, Y. M., & Rind, S. (2024). Frequency of UTI amongst patients taking SGLT 2 inhibitors. Cuestiones de Fisioterapia, 53(03), 5090-5095.
https://doi.org/10.48047/7w7d9730
15. Shaikh, K., Junejo, A. M., Nawaz, A., Ali, M., Ahmed, S., Yaseen Khan, R. T., Mehdi, S. M., & Nasir, A. (2025). Frequency of urinary tract infections in patients taking sodium-glucose cotransporter-2 (sglt-2) inhibitors. Insights-Journal of Health and Rehabilitation, 3(3 (Health & Rehab)), 28-33.
https://doi.org/10.71000/pwpwjg34
16. Hussain, M., Hussain, A., Rehman, H. U., & Iqbal, J. (2021). Prevalence of Genitourinary infections with sodium glucose Co-transporter-2 (sglt2) inhibitors in patients with type 2 diabetes. Pakistan Journal of Medical and Health Sciences, 15(10), 2804-2807.
https://doi.org/10.53350/pjmhs2115102804
17. Azhar, M., Hanif, M., Rafi, S., Ziauddin, M., Sohail, N., & Kumar, R. (2023). Frequency of urinary tract infections in type 2 diabetes patients taking sodium-glucose co-transporter-2 (SGLT2) inhibitors to regulate their blood sugar level. J Pharm Neg Results, 14(4), 95-99.
18. Radi, S., Almutairi, M., Alghamdi, A. S., Alzahrani, M., Alghamdi, S., Almalky, N., Alharbi, B., Altuwaylie, T. M., Marwani, F., & Saber, W. (2024). Tolerability of sodium-glucose Co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A retrospective cohort study. Cureus.
https://doi.org/10.7759/cureus.75798
19. Ubaid, M., Khan, S., Wazir, N., Ullah, I., Rehman, M. U., & Ahmed, I. (2024). Urinary tract infection (Uti) in postmenopausal women with type 2 diabetes mellitus using sodium glucose Co transporter 2 inhibitors (sglt-2 I). Journal of Medical Sciences, 32(2), 143-146.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
